European genomics: think big or small?  by Gross, Michael
Now that the human genome is
sequenced (more or less), what shall
we do with it? If we want to benefit
from it to gain an improved
understanding of the genetic basis of
disease and the different responses
to drugs, knowing the three billion
bases that all of us have in common
is only the beginning. The second
leg that future medical genetics will
need to stand on is the knowledge of
the several million bases that we
don’t have in common, from which
the most widespread types of genetic
variation originate. The most
important group of variabilities is
described as ‘single nucleotide
polymorphisms’ or SNPs. They are
defined as base exchanges occurring
in at least 1% of a population, as
opposed to a random mutation that is
normally found with a frequency of
much less than 1%.
SNPs essentially define the
genetic differences between
individuals, including — most
importantly for medical
research — their different
susceptibilities to diseases and
different responses to drugs. So far,
the links between genes and diseases
have only been established in
relatively few, mostly rare and
monocausal diseases, like cystic
fibrosis. How can the more common
multifactorial diseases (like coronary
heart disease or type II diabetes) be
linked to patterns in genetic
variability? This is one of the major
challenges awaiting science in the
postgenomic era, and there are
different approaches to it, which can
be broadly divided into those which
use small, inbred populations and
those based on large populations. 
One large-scale study is being
launched in the UK with funding
from the Medical Research Council
and the Wellcome Trust. The plan is
for a major long-term study of
around 500,000 middle-aged
volunteers as a representative
sample of the UK population.
Alongside genetic analysis, basic
measurements such as height,
weight and blood pressure  will be
made and followed up with data on
health and lifestyle. The hope is that
within a few years meaningful
research on a significant number of
ill people should be possible.
Researchers who believe in the
benefit of studying small
populations are the luckier ones in
practical terms, as they get to work
in sunnier climates. Hotspots of
genomics research have emerged in
remote Italian villages such as
Perdasdefogu and Talana, both
situated in the Ogliastra region in
Northwestern Sardinia, near the
town of Alghero. Between them,
these villages have less than 4000
inhabitants, who mostly descend
from a small group of families who
founded the villages around
500 years ago. In the case of Talana,
it is precisely known that all 1400
villagers descend from eight males
and eight females. Less than 5% of
marriages have been to outsiders. 
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The man who pushed these
villages to the forefront of genomics
research is Mario Pirastu, a native
Sardinian who returned to his island
after research work in San Francisco
and is now the director of the
Istituto de Genetica Molecolare in
Alghero, funded by Italy’s national
research council, CNR. He is a firm
believer in the approach that uses
small inbred populations which
should be less than 200 generations
old. Outside Sardinia, the best-
known cases are the Amish, some
communities in Newfoundland,
along with some villages in
Switzerland. Pirastu and his
colleagues argue that the genetic
homogeneity of such small inbred
populations makes it easier to track
down genetic factors contributing to
multifactorial diseases, as differences
irrelevant to the questions under
study will be producing less noise
than they would in a large and
diverse population. The main
criterion used in such studies is
linkage disequilibrium which
essentially relies on the fact that
genes are more likely to be passed
on together, the closer they are on
the chromosome. 
Last summer, Pirastu obtained
large scale support from various
sources to set up an international
research centre at Perdasdefogu and
make the most of the rare and
valuable gene pool found in this
village. For the native population,
this comes mainly as a welcome
boost to the local job market, so the
local politicians are quite supportive
of the research. In other remote parts
of Italy, similar projects are on the
way. Paolo Gasparini and his
coworkers from the Medical
Genetics Service at Rotondo have
picked the Southern Italian village of
Carlantino, where the rate of
marriage within the community was
99.5% over the last century. And in
the surroundings of Naples, Graziella
Persico is studying a whole cluster of
similarly isolated villages. 
However, this cottage industry
also has its limitations. Although
some disease-related variants will be
abnormally frequent in such inbred
populations, others will be totally
absent and thus cannot be studied
until one finds another suitable
group that has them. This is where
large-scale, nationwide genome
projects are hoping to make their
mark. The oldest study of this kind
is the one in Iceland. Like the
Sardinian villages, Iceland has
remained isolated for centuries, but
it started from a much bigger gene
pool, gradually expanding to today’s
population of 275,000. 
In December 1998, the Icelandic
parliament passed a bill enabling the
creation of a centralized medical
database, after a year-long public
debate on ethical and privacy
problems arising from this proposal.
Much of the debate was based on the
issue that a private biotech company,
namely deCode Genetics, chaired by
the Icelandic geneticist Kari
Stefansson, is running and
controlling the database. To defuse
this issue, the parliament created a
Governing Committee including
members of the public, that acts as a
kind of consumer watchdog to
oversee this project. 
Public debate is remarkably
absent in a country that tries to beat
Iceland’s genome project with larger
numbers and a more diverse gene
pool: Estonia. Although the core
Estonian population has been
sedentary on the Baltic shore for
more than 5000 years, some mingling
with neighbours must have taken
place. Among today’s 1.45 million
citizens of the Estonian Republic,
Russians form the strongest ethnic
minority with 28%. Thus, the
proponents of the Estonian Genome
Project argue, Estonians are less
exceptional than the isolated
populations, while still being
sufficiently homogenous for
meaningful genetic studies.
The Estonian Genome
Foundation (EGF) is currently
seeking corporate sponsors and
parliamentary approval for what
would become the world’s largest
database of medical, genetic and
genealogical data. More than 90%
of the Estonian population are
expected to consent to part with
50 ml blood and their medical
records.If successful, this project
would result in a database holding
sensitive information on 1.3 million
individuals, including people’s
health status, diseases, important
health and behavioural risks and
genealogical information, as the
EGF cheerfully proclaims on its
website. Even though the names of
the subjects will be replaced by
anonymous codes, it is hard to
imagine how a database of this size
and with such sensitive personal
information could be handled
without at least a small risk of
leakage and misuse of data. Using
only DNA samples from deceased
hospital patients (who have
consented before dying) may be a
way around the privacy problems
arising from such large projects. 
While the village-sized projects
certainly have the advantage that
the smaller databases are more
easily kept safe from misuse, ethical
issues are far from absent in these
cases. Like in anthropological
studies of native tribes in Africa or
South America, the very remoteness
of the villages under study throws
up ethical concerns. In this case the
question has to be asked whether
agreement to give a blood sample
constitutes informed consent to a
full scale characterization of
genomic markers. As even the
geneticists don’t know yet what
these markers will tell them, the
subjects of the research cannot
possibly know — and probably lack
the ability to imagine — what kind
of information about themselves
they are handing over. If geneticists
don’t want to limit themselves to
studying the DNA of deceased
patients, they may have to redefine
what informed consent means in the
postgenomic era. 
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